Ulcerative Colitis 2 - CPL | US
Offer Details: | |
|---|---|
| Offer Name: | Ulcerative Colitis 2 - CPL | US |
| Payout: | $52.00 / CPA |
| Preview: | Preview Landing Page |
| Categories: | Ecommerce |
| Network: | DYNU IN MEDIA |
| Last Updated: | May 18, 2025 |
| Countries: | US |
Ages: 18+
Gender: Any
Study Description:
The purpose of this clinical study is to see how effective an investigational medication is at helping to treat adults with moderately to severely active Ulcerative Colitis (UC). The study medication is currently FDA approved to treat several inflammatory conditions and is being explored as a new therapy option for UC patients. You may be asked to attend a screening visit and complete a screening endoscopy to determine if you are eligible to enroll in the study. If enrolled, you will receive either the medication being tested in this study or a placebo which will be self-administered as an injection, once a week, for one year. Your total participation will last approximately 16 months and you will be asked to attend 6 doctor’s visits. During these visits, you will complete various diagnostic and laboratory tests. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated for time and travel. The doctor’s office conducting the study will be able to provide you with more information about the study requirements.
Qualifications:
- Must be diagnosed with UC for 3 months or longer and confirmed with an endoscopy procedure (such as a flexible sigmoidoscopy or colonoscopy)
- Must be currently experiencing symptoms of UC such as frequent stools and rectal bleeding
- Currently taking prescription medication for your Ulcerative Colitis (common examples may include oral corticosteroids, 5-ASA compounds, or medications that stimulate or suppress the immune system)
- Cannot have ever taken dupliumab (Dupixent) or Rituxan (rituximab) or Campath (alemtuzumab)
- Cannot also be diagnosed with lupus, rheumatoid arthritis, or kidney disease that requires dialysis
- Cannot have ever been diagnosed with short bowel symdrome or crohn's disease
PROOF REQUIRED
Mailer Access: Key: https://www.affiliateaccesskey.com/m-dzkm-s96-fe921c0182d0bc6f14049e7d22312e35
Optout Link: https://www.twonailhall.com/o-dzkm-s96-36e3b037ec63dddac266bb83682f020c
Gender: Any
Study Description:
The purpose of this clinical study is to see how effective an investigational medication is at helping to treat adults with moderately to severely active Ulcerative Colitis (UC). The study medication is currently FDA approved to treat several inflammatory conditions and is being explored as a new therapy option for UC patients. You may be asked to attend a screening visit and complete a screening endoscopy to determine if you are eligible to enroll in the study. If enrolled, you will receive either the medication being tested in this study or a placebo which will be self-administered as an injection, once a week, for one year. Your total participation will last approximately 16 months and you will be asked to attend 6 doctor’s visits. During these visits, you will complete various diagnostic and laboratory tests. Participants who qualify for the study will receive trial-related procedures and study medication at no cost and may be compensated for time and travel. The doctor’s office conducting the study will be able to provide you with more information about the study requirements.
Qualifications:
- Must be diagnosed with UC for 3 months or longer and confirmed with an endoscopy procedure (such as a flexible sigmoidoscopy or colonoscopy)
- Must be currently experiencing symptoms of UC such as frequent stools and rectal bleeding
- Currently taking prescription medication for your Ulcerative Colitis (common examples may include oral corticosteroids, 5-ASA compounds, or medications that stimulate or suppress the immune system)
- Cannot have ever taken dupliumab (Dupixent) or Rituxan (rituximab) or Campath (alemtuzumab)
- Cannot also be diagnosed with lupus, rheumatoid arthritis, or kidney disease that requires dialysis
- Cannot have ever been diagnosed with short bowel symdrome or crohn's disease
PROOF REQUIRED
Mailer Access: Key: https://www.affiliateaccesskey.com/m-dzkm-s96-fe921c0182d0bc6f14049e7d22312e35
Optout Link: https://www.twonailhall.com/o-dzkm-s96-36e3b037ec63dddac266bb83682f020c
DYNU IN MEDIA
DYNU IN MEDIA is a super match CPA/CPL network for earning money online that provides you with all techniques allowing you to monetize your traffic in all channels. We guarantee outstanding support to our publishers. Our devoted team with experience in the affiliate marketing industry will give you full-assist, direct offers in a wide-ranging variety of verticals and top GEOs, and a flexible payment schedule of NET15 & NET30. Hitting more than 20,000 leads generated daily for over 200 influential clients, along with an increasing number of HQ publishers to 300 and more, DYNU IN MEDIA is taking high pride in our professionalism and high integrity.
